Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $TLPH
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/28/2025 | $4.00 | Buy | Rodman & Renshaw |
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study
Submission of a Prior Approval Supplement for a reduction in the number of patients in the NEPHRO CRRT study is expected within the coming week The FDA agreed to two additional protocol changes expected to accelerate enrollment in the NEPHRO CRRT study SAN MATEO, Calif., Jan. 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that following a meeting with the U.S. Food and Drug Administration (FDA), the agency has agreed to review a Prior Approval Supplement (PAS) requesting a reduction in the number of patient
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update. "Our NEPHRO CRRT study has gained momentu
Rodman & Renshaw initiated coverage on Talphera with a new price target
Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00
CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $3,200 worth of shares (5,000 units at $0.64), increasing direct ownership by 2% to 208,066 units (SEC Form 4)
4 - TALPHERA, INC. (0001427925) (Issuer)
CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $3,650 worth of shares (5,000 units at $0.73), increasing direct ownership by 3% to 203,066 units (SEC Form 4)
4 - TALPHERA, INC. (0001427925) (Issuer)
CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $7,598 worth of shares (7,260 units at $1.05), increasing direct ownership by 4% to 198,066 units (SEC Form 4)
4 - TALPHERA, INC. (0001427925) (Issuer)
Chief Engineering Officer Dasu Badri N covered exercise/tax liability with 2,644 shares, decreasing direct ownership by 9% to 27,011 units (SEC Form 4)
4 - TALPHERA, INC. (0001427925) (Issuer)
Chief Financial Officer Asadorian Raffi covered exercise/tax liability with 3,245 shares, decreasing direct ownership by 9% to 32,214 units (SEC Form 4)
4 - TALPHERA, INC. (0001427925) (Issuer)
CHIEF EXECUTIVE OFFICER Angotti Vincent J. covered exercise/tax liability with 10,575 shares, decreasing direct ownership by 5% to 190,459 units (SEC Form 4)
4 - TALPHERA, INC. (0001427925) (Issuer)
Talphera Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - TALPHERA, INC. (0001427925) (Filer)
Talphera Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
8-K - TALPHERA, INC. (0001427925) (Filer)
SEC Form 10-Q filed by Talphera Inc.
10-Q - TALPHERA, INC. (0001427925) (Filer)
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive
Talphera Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Five sites actively screening with multiple patients having completed the study; two additional institutions expected to begin screening in the fourth quarter totaling seven active sites Cash and investments at September 30, 2024 of $11.1 million Conference call and webcast to be held Wednesday, November 13, 2024 at 4:30 pm ET SAN MATEO, Calif., Nov. 13, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced third quarter 2024 financial results and provided a corporate update. "Our NEPHRO CRRT study has gained momentu
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024
SAN MATEO, Calif., Nov. 6, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2024 financial results after market close on Wednesday, November 13, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast
Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update
NEPHRO CRRT study patient screening has initiated at multiple clinical sites The safety and effectiveness of nafamostat is being assessed in the NEPHRO CRRT registrational study in 166 patients at up to 14 clinical sites Cash and investments at June 30, 2024 of $14.0 million Conference call and webcast to be held Wednesday, August 14, 2024 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2024 financial results and provided a corporate update. "We're excite